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Use of cardiac implantable devices and catheter ablation is steadily increasing in Western countries following the positive results of clinical
trials. Despite the advances in scientific knowledge, tools development, and techniques improvement we still have some grey area in the
field of electrical therapies for the heart. In particular, several reports highlighted differences both in medical behaviour and procedural
outcomes between female and male candidates. Women are referred later for catheter ablation of supraventricular arrhythmias, especially
atrial fibrillation, leading to suboptimal results. On the opposite females present greater response to cardiac resynchronization, while the
benefit of implantable defibrillator in primary prevention seems to be less pronounced. Differences on aetiology, clinical profile, and devel-
opment of myocardial scarring are the more plausible causes. This review will discuss all these aspects together with gender-related differ-
ences in terms of acute/late complications. We will also provide useful hints on plausible mechanisms and practical procedural aspects.
...................................................................................................................................................................................................
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Introduction
Despite the improvements in knowledge and technologies, in the
1990s the Society for the Advancement of Women’s Health
Research criticized the exclusion of women from most clinical re-
search.1 The differences between men and women go beyond sex
hormones and anatomy, entailing all the aspects of human life. These
factors reflect on the outcomes of the treatments we adopt in com-
mon clinical practice. This review will focus on the various effects of
gender on electrical therapies for the heart: electrophysiology (EP)
procedures with substrate ablation and treatments based on implant-
able devices for cardiac pacing/defibrillation (CIED).
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Radiation exposition is a known risk factor for cancer. About 1/1000
individuals will develop cancer from an exposure similar to what pro-
vided by CT scan or atrial fibrillation (AF) ablation.2,3 Sensitivity to ra-
diation is different between age and sex, being women of childbearing
age the more sensitive (Figure 1).4 After a 64-slice CT coronary angi-
ography the lifetime risk of radiation-related cancer was reported to
be 2.4–4.8 times greater in women.5,6 Breast cancer accounted for
up to 40% of the total cancer risk in younger women,6 followed by
lung cancer.5 However, several technical limitations of these studies
have been reported.7 Lawler et al.8 showed in population-based lon-
gitudinal cohort of 82 861 patients undergoing coronary angiography,
that for each mSv women were more likely to develop a cancer than
men also after adjusting for age, non-cardiac exposure, and covariates
(HR 1.005 vs. 1.002). The increased risk of cancer was confirmed to
be primarily due to lung cancer, while incidence of breast cancer did
not reach statistical significance. This discordance with CT scan stud-
ies5,6 is probably due to a more advanced age of patients (almost
all >50 years)8 explaining also why age was not a determinant of
radiation-associated risk of cancer. Regarding CIED procedures,
Pedersen et al. conducted a ‘similar’ population-based study on ICD
recipients examining the risk of ICD-related cancer, by linking the
Danish National Registry of Patients and the Danish Cancer Registry.
They detected a 10% excess risk of cancers during a median follow-
up of 2.8 years, confined to tobacco-related cancers in patients with
ischaemic heart disease without difference between genders, show-
ing that smoking habit was the plausible driver.9 The authors con-
cluded that the role of exposition for CIED therapy to promote
cancer is marginal. However, three considerations should be raised:
(i) The follow-up period was too short since previous studies showed
a 5- to 10-year latency between radiation exposure and cancer devel-
opment;8 (ii) These findings may not be applied to CRT and complex
procedures since patient can be exposed to a dose five-fold higher
(on average 22 mSv vs. 4 mSv)3,10; (iii) All these data5,6,8,9 derive from
very large registries, enabling the evaluation of very rare events, but
lacking of some important factors such as height, weight, and BMI
that should be considered.3
Several mapping tools have been developed that can already per-
mit ‘near-zero’ fluoroscopic exposure during ablation of supraven-
tricular arrhythmias. The No-PARTY trial11 evidenced that a ‘near-
zero’ approach, for ablation of supraventricular arrhythmias, was
associated with equivalent results, as compare to standard
approaches, both in terms of success (97% vs. 96% at 6 months) and
safety (complication rate of 0.01% vs. 0.01%) . The median reduction
of exposure of about 8 mSv for patients and 24 microSv for the oper-
ators.11 This lead to a 96% reduction of the risk of developing a
procedure-related cancer (from 0.267% to 0.0089%). Moreover, in
72% of the patients radiation were not used at all. These results are
really promising for women of childbearing age, since no definite data
are currently available on the minimum ‘safe’ radiation exposure for
women planning to become pregnant. Indeed, there are no studies
aimed at clarifying how long it is advisable to wait before a pregnancy
after an EP procedure, and how to manage a pregnant woman requir-
ing an invasive approach for severe recurrent arrhythmias. However,
there is a general agreement that, during pregnancy, an ablation pro-
cedure should be discouraged; then, in women with a history of
major rhythm disturbances, an elective procedure should be pro-
grammed at least 6 months before planning a pregnancy.
Gender differences in peri-procedural
sedation
Intravenous sedation represents a relevant issue in CIED and EP pro-
cedures since it can provide many benefits but also rise several con-
cerns (see Supplementary material online, Table S1).12 Notably, there
is a continuum between sedation and general anaesthesia and scales


















15 25 35 45 55 65
Age at exposure (y)
Cancer incidence Cancer mortality
15 25 35 45 55 65





Figure 1 Lifetime attributable risk of cancer incidence and mortality induced by radiation exposure during RFA procedures by age at exposure for
females and males, for a mean effective dose of 19.1 mSv per procedure. Modified from Casella et al.4
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specific characteristics may affect pain/discomfort during procedures,
but despite the broad number of studies, we still have conflicting evi-
dence on the role of gender in pain perception.13–15 Despite the rele-
vance of the topic, only a limited number of investigations evaluated
pain in EP/CIED procedures. Ezzat et al.16 reported that excess of
pain is the principal source of disappointment after AF ablation, with
a high prevalence (about 56% of the patients). A Swedish study
randomized 80 consecutive patients to pulmonary vein isolation
under standard sedation (morphine plus diazepam) vs. an improved
analgesic strategy (pre-medication with oral midazolam plus intraven-
ous alfentanil and midazolam) with half of the patients treated with
radiofrequency and the others with Cryo-ablation.17 Women experi-
enced more pain than men (P = 0.01), while both the active analgesic
strategy and the use of Cryo-ablation was associated with a reduced
discomfort. More recently, Bode et al.18 provided a broader picture
analysing the incidence of acute post-procedural pain in consecutive
patients after EP (49) and CIED (53) procedures. Sixty per cent of
the patients reported moderate-to-severe pain in the first 24 h des-
pite the use of analgesics, especially back pain (44%) and at the site of
the CIED pocket (39%). Female sex was the only variable significantly
associated with early post-procedural pain at multivariate analysis
(P = 0.046). Finally post-procedural pain is not limited to the acute
phase, especially after CIED procedures, a phenomenon that can lead
to prolonged disability of the ipsilateral arm in a significant portion of
the patients.19–21 Gender specific responses to sedation agents pro-
vide another source of variability both in terms of type/dose adjust-
ment and occurrence of side effects,22 which however still needs to
be explored since women are often excluded also from basic/clinical
studies of anesthesia.23
The effect of gender on CIED implanting
technique
Previous studies on breast cancer showed that conserving surgery
(vs. mastectomy) provided several benefits in terms of body image,
psychological/social adjustment and compliance to overall treat-
ment.24,25 The ICD implanting technique evolved during time with
the downsizing of the can moving from the abdomen to be subclavian
area, initially submuscular and later subcutaneous.26 In the same
period Belott et al. reported two cases of a particular approach
involving the deployment of the ICD lead through 1 cm incision to
the surface of pectoralis muscle followed by a second 4 cm long infra-
mammary incision to create the device pocket above the pectoralis
muscle and behind the mammary glandule with tunnelization of the
lead.27 This approach was followed by a single-incision approach
based on the puncture of the axillary vein based on a peripherally
placed intravenous guidewire and creation of the subpectoral device
pocket by an incision near the anterior axillary line.28 The two larger
experiences reported in literature come from Giudici et al.29 and
Persichetti et al.30 Both groups created a retropectoral inframam-
mary device pocket, while the difference was in the venous access
that was axillary (Giudici et al.29) or subclavian (Persichetti et al.30)
with a small separate incision followed by lead tunnelization. All these
studies showed high level of CIED acceptance. However, it has to be
underlined that despite being promising alternatives, we still lack of
robust data with long-term follow-up of patients undergoing these
implanting techniques: there are few studies and those that exist have
enrolled a small number of patients, without direct comparison with
standard approaches.31,32 From a technical point of view higher im-
pedances have been reported33 without evident effects on defibrilla-
tion threshold. A more recent report on 20 patients with
submammary (subglandular and above the pectoralis muscle) ICD
showed a significative increase in ventricular pacing threshold an a re-
duction in lead impedance (from 0.6 ± 0.2 V and 621 ± 223 ohms vs.
1.6 ± 0.6 V and 471 ± 89 ohms) with 2 lead dislodgement and 3 late
lead revision 15%).32 The last technological advancements can poten-
tially favour the development of more cosmetic approaches while
providing several other benefits (Figure 2).34,35
Gender and outcomes of EP/CIED
procedures
The effect of gender on outcomes after
ICD implantation
The survival benefit provided by ICD in women is a subject of debate.
Despite the absence of a clear gender effect showed by the original tri-
als,36–44 three metanalysis showed less benefit in female subjects.45–47
However, under-representation of women in cardiac device trials
(8–29%) limited these analyses. Focusing on real-life data there is gen-
eral agreement with lower occurrence of appropriate ICD therapies
in female subjects.48–52 However, overall survival of implanted patients
and benefit with respect to non-implanted subjects seems not to be af-
fected by gender.48,51–55 This can be explained by the higher preva-
lence in men of myocardial scarring (especially post-infarction) leading
to a higher change of sudden death for shockable arrhythmias, while fe-
males die relatively more by asystole, pulseless electrical activity and
pump failure.56–59 The negative results of the recently published
Danish Study to Assess the Efficacy of ICDs in Patients with Non-
ischaemic Systolic Heart Failure on Mortality trial60 may support this
hypothesis since it evidenced that patients with non-ischaemic left ven-
tricular dysfunction seem not to benefit from ICD despite indication
to CRT without gender difference (at subgroup analysis).
There is a broad spectrum of mental symptoms/diagnoses in ICD
carriers: anxiety is the most common with a prevalence between 7.6
and 46%, similarly depression is another typical disorder occurring in
14–41% of the subjects.61 These factors and the broader concept of
quality of life (QoL) are relevant since they have been associated with
all-cause and cardiac-related mortality in patients with an ICD62–65
and CRTD.66,67 Several characteristics have been associated with
poorer QoL and occurrence of anxiety/depression: ICD shock thera-
pies, type D personality, non-CRT device, younger age and female
gender. Females in particular, seem to express more anxiety (con-
nected to procedure, shock, and death) and concerns for body image
while depression seems to be equally expressed among the two
sexes.62–65,67–74 Notably, these studies present several limitations
(patient selection, assessment measures, population size, time of ad-
ministration since ICD implant, follow-up duration, and response
rate) and adjusting for covariates has shown to decrease the gender-
effect especially at long-term after CIED implant.75 In any case ac-
cording an adequate pre/post-procedural patient counselling, patient
support and tailoring of CIED procedures may positively impact on
these symptoms and QoL.76–78
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The effect of gender on response to CRT
Several randomized studies demonstrated a greater benefit of CRT
in women than in men (Table 1).79–86 This has been confirmed in real
world settings,87,88 also at long-terms.89 Despite the increased preva-
lence of cardiovascular (hypertension, coronary artery disease, AF)
and non-cardiovascular (diabetes, COPD, and chronic renal failure)
comorbidities in the elderly, women present a higher response to
CRT also in the advanced age.90–93 The reason for these findings is
unclear. Possible explanations are: (i) the higher risk of HF for women
vs. men which may lead to boost the preventive effects of CRTD, (ii)
a standard QRS duration of 10 ms lower in women vs. men94 leading
to a greater conduction disturbance and possibly to a greater chance
of response. More recently, in the MADIT-CRT trial, women pre-
sented a higher performance with CRT-D (about 70% reduction in
HF hospitalization or death) independently of QRS duration
(< vs. > 150 ms).83 This was confirmed by a FDA metanalysis95 show-
ing that women with a QRS 130–150 ms benefit more than men
from CRT. Notably this is a IIA indication (ACCF/AHA/HRS guide-
lines).96 However, while >50% HF patients are women only <25% of
the enrolled patients in HF clinical trials are females.
Gender differences in acute
complications of CIED procedures
Despite no difference in mortality found in real-life studies, several
authors reported a greater incidence of CIED-related complications
for female subjects, with an OR ranging between 1.32 to 1.55 for
overall complications.48,55,97–99 The National Cardiovascular Data
Registry (NCDR) ICD Registry found a 32% greater incidence in
overall in-hospital complications (4.4% vs. 3.3%, P < 0.001), mainly
lead dislodgements, vessel injuries, pneumothorax, pericardial effu-
sion.99 This was confirmed also by the Ontario ICD Database which
extended the perspective to post-discharge <45 days and <1 year
(OR 1.50 and 1.55, respectively)48 and a recently published metanaly-
sis.100 This also applies to pacemaker setting as shown by the analysis
of two European registries: the Danish Pacemaker and ICD Register
(DPIR)101 and the database of the Institute of Quality Assurance
Hessen (Germany).98 Since the more frequently reported complica-
tions increased in women are lead dislodgements, vessel injuries,
pneumothorax and pericardial effusion the principal explanations for
these findings are: the sicker profile (in terms of aging, progression of
cardiac disease, comorbidities), the smaller body size and the need
for different device (more frequently CRT). Notably, these results
were also confirmed after adjusting for the mentioned parameters in
most of the reports, but it the high number of variables coupled with
the low number of events and enrolled female subjects significantly
limit any post-hoc ‘adjustment procedure’.
The effect of gender on CIED infection
and lead extraction
According to current literature, males seem to be more vulnerable
to many infectious pathogens102 and in particular to community/
hospital-associated bloodstream infections (BSI) and surgical site
Figure 2 Schematic representation of the different aesthetical approaches reported in literature for implantation of CIED by (A) Giudici et al.29 (B)
Persichetti et al.30 (C) Shefer et al.28 For comparison new approaches based on recent leadless technologies for ICD (D)34 and PM (E)35 are reported.
Incisions are reproduced with white lines, generator incision with capital letter and additional incisions with small letters. For graphical purposes, the
devices implanted with A and B approaches are represented in the right side of the body, even if they are commonly performed on the left side.29,30
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infections (SSI)103 due to various factors,102,104–110 as confirmed by
several observational cohort/population studies (Table 2).98,99,111–117
Notably, the two studies showing no gender-effect on CIED infection
(in italics in Table 2)98,99 limited the analysis to pre-discharge compli-
cations, losing sensitivity to CIED infections which usually occur sev-
eral months later (confirmed by the low prevalence reported).118
When CIED infection occurs, the only effective approach is the com-
plete extraction of all the PM/ICD system. Several authors reported
that female sex and a BMI below 25 kg/m2 are associated with an
increased risk of peri-procedural complications. Smaller vessels and
the higher chance of lesion by traction/pressure or the delivery of
additional energies by powered sheaths can be an explanation to
these findings.119 Notably, a recent metanalysis did not confirm the
presence of any association between female sex and outcomes both
in terms of technical success and clinical outcomes.120 However,
male sex prevailed in all the studies included in the metanalysis,
being >_75% in one third of them (notably 6 studies did not reported
gender prevalence at all).120 Taken together these data show once
again the limitations provided by existing literature in terms of statis-
tical power for an adequate gender analysis of procedural outcomes
incidence. The final results of the Electra registry will provide add-
itional hints on this topic.121
The effect of gender on catheter ablation
procedures
A large prospective cohort study122 reported a success rate for
AVNRT ablation of 98.1% and a recurrence rate of 1.5% at 63 ± 38
months. Young age (<20 years, OR 14.1) and female sex (OR 3.6)
were the two independent predictors of late recurrence. The authors
concluded that a more conservative approach could explain this find-
ing122 confirming the previous findings on a cohort study enrolling 894
patients.123 Farkowski et al.124 reported on a series of 82 patients
undergoing ablation for AVNRT/AVRT showing an equivalent re-
source utilization in both genders in the year before the procedure
but antiarrhythmic drugs were more often prescribed to women
(30% vs. 8%). After ablation there was no difference in health-related
quality of life (QoL) while females reported a significantly higher per-
sistence of arrhythmia-related symptoms, especially ‘heart skipping’.
Regarding AF, women are referred to ablation less often than men
(3% vs. 6%).125,126 The results on ablation outcome from published
cohorts are discordant: while some authors provided similar acute
and late success rate,127 other reported a lower success rate in female
patients both in acute and at subsequent follow-up.128–130 However,
these findings can be attributable to a different level of disease pro-
gression/evolution before the procedure in the various cohorts, due
to late referral (60 vs. 47 months)127 with advanced left atrial remod-
elling (diameter 44.0 ± 6.5 vs. 40.6 ± 6.3 mm)127 and high prevalence
of long-standing persistent AF (27% vs. 20%)128 showing non-
pulmonary vein sites of firing (50.4 vs. 16.3%).128
The same authors also showed a higher incidence of procedure-
related haematomas in women (2.1–6.8% vs. 0.7–0.9%). With regards
to overall complications, the incidence of major complication has
been reported to be about 4–5% for AF ablation,129,131–133 with two
major independent predictors of events, corresponding to advanced
....................................................................................................................................................................................................................
Table 2 Large cohort studies of CIED candidates/carriers reporting incidence of CIED infection by gender










Prospective 6319 pts 0.68 M: 0.79 F: 0.74 (0.39-1.4) NS
F: 0.47
Uslan et al.111 1975, 2004 Retrospective,
population-based
cohort study
1524 pts 5.0 M: 6.1 Not
reportedF: 3.7




1.6 M: 2.0 0.01
F: 1.1
Nery et al.115 1 July 2003,
20 March 2007
Prospective 2417 pts 1 M: 1.11 NS
F: 0.9
Johansen et al.114 1 January 1982,
31 December 2007




M: 1.3 F: 0.60 (0.51-0.71) 0.001
F: 0.8






2.9 M: 3.1 Not
reportedF: 2.7







0.9 M: 1.11 M: 1.66 (1.36-2.02) 0.001
F: 0.7
Peterson et al.99 January 2006,
December 2007
Retrospective 161 470 ICD
implantation
0.03 M: 0.03 NS
F: 0.03
Nowak et al.98 2003, 2006 Retrospective 17 826 PM
implantation
0.11 M: 0.12 NS
F: 0.10
CDI, cardiac device infection; CI, confidence interval; F, female; ICD, implantable cardioverter defibrillator; M, male; N, number of patients/procedures; NS, not significant; OR,
odds ratio; PM, pacemaker.
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age (OR 1.86 for age 65–74 vs. 18–44) and female sex (OR 1.38).129
Since the major randomized controlled trial on AF ablation did not
reported sex-specific analysis of the outcomes and complications,134
data come from large cohort studies (Table 3).129,135–140
Notably, obesity is a further modifying factor, associated with an
increased risk of procedural complications (Shoemaker et al.141 re-
ported an odds of complications increased 3.1-fold in patients with
high BMI). Finally, no significant differences in the outcomes of abla-
tion for atrial flutter and ventricular arrhythmias have been reported,
although females were largely underrepresented in studies on abla-
tion of ventricular arrhythmias.142
Conclusions
The available data summarized in this review support the presence of
an influence of gender on several aspects of EP/CIED based therapies.
In some cases the mechanism is better documented and character-
ized. Women receive greater benefit from CRT and CIED infection
rate is inferior. However, women experience a higher rate of acute
complications during CIED implantation and haematomas after EP
ablation. Finally, EP/CIED procedure-related pain are more frequent
in women. There are some topics discussed in this review for which
clearly need further investigations. Females seem to receive lower
benefit from ICD in primary prevention but the reason is still ob-
scure. The more cosmetic CIED implanting techniques, while attract-
ive to improve device acceptance, still need direct comparison to
standard approaches to confirm an equivalent performance at long-
term. The role of gender on the efficacy of EP ablation needs studies
including a larger proportion of women. The higher complication risk
reported by females undergoing lead extraction has not been con-
firmed in more recent investigations. These data highlight the need to
design new clinical researches aimed at mitigating the existing gaps
between men and women in this field.
....................................................................................................................................................................................................................
Table 3 Large cohort studies (>1000 patients) comparing outcomes of catheter ablation for atrial fibrillation in
women and men (percentage values and ORs have been reported only when P < 0.05 in the publication)





Baman et al.140 Prospective 1642 procedures 26 60±10 N.R. N.R. F: higher ratio (OR = 2.32)
of any complications.






Kaiser et al.135 Retrospective
(medical claims)
21 091 patients 29 M: 58±11 12 F: higher ratio of
rehospitalization for
AF (OR = 1.12), but less
likely to have repeat
AF ablation (OR = 0.92)
or cardioversion (OR = 0.75)
F: higher risk of 30-day vascular
complications(2.7% vs. 2.0%)
and tamponade (3.8% vs. 2.9%)
F: 62±11




Shah et al.129 Retrospective 4156 patients 29.3 61.7 1 N.R. F: higher ratio (OR = 1.38) of
inpatient complications or
30-days rehospitalization.
Takigawa et al.137 Prospective 1124 patients 23.1 M: 60±11 31.7, after
first CA
SR maintenance was similar
between sexes after the
first CA; for repeated
procedures was significantly






Zylla et al.136 Retrospective 3652 patients 33 M: 59±11 12 F: higher AF recurrence rates
(50.2% vs. 45.4%; OR = 1.19)
F: higher ratio of major inhospital
complications(1.9% vs. 0.8%)
and femoral access site
complications (6.2% vs. 3.3%)
F: 64±10
N, number of patients/procedures; F, female; M, male; CA, catheter ablation; N.R., not reported; OR, odds ratio; AF, atrial fibrillation; SR, sinus rhythm.
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Treatment of intramural ventricular tachycardia in cardiac sarcoidosis with
transcoronary ethanol ablation
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A 67-year-old man with sarcoidosis presented with recurrent
ventricular tachycardia (VT) despite treatment with amiodar-
one. Cardiac magnetic resonance imaging demonstrated
delayed enhancement of the mid-myocardium in the inferolat-
eral wall and septum (Figure, upper panel) and cardiac positron
emission tomography–computed tomography (PET-CT)
showed a perfusion defect with increased uptake of 18F-fluoro-
deoxyglucose in the same region. Two inducible VTs were both
mapped to the cardiac crux along the inferior interventricular
septum (RBBB, superior axis and LBBB, superior axis, respec-
tively). Prior attempts at radiofrequency (RF) catheter ablation,
including epicardial and bipolar transmural RF ablation, as well
as haemodynamic support with extracorporeal membrane oxy-
genation, were not successful. Because of VT storm, the patient
underwent transcoronary ethanol ablation, which targeted a
right posterolateral (RPL) branch which supplied this region.
Balloon occlusion of the distal RPL during VT reproducibly ter-
minated the tachycardia within 30–50 s (Figure, lower panel),
and ethanol ablation prevented inducibility. During 2 years of
follow-up, he required one other endocardial ablation to treat
VT from a lateral LV location, and then had only one recur-
rence. We propose that alcohol ablation should be considered
in patients with sarcoidosis who have intramural VTs that fail
endocardial and epicardial ablation and are refractory to con-
ventional therapy.
The full-length version of this report can be viewed at: http://www.escardio.org/Guidelines-&-Education/E-learning/Clinical-cases/
Electrophysiology/EP-Case-Reports.
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